Literature DB >> 11380403

bcl-2 expression in non-Hodgkin's lymphomas is not associated with bcl-2 gene rearrangements.

G Papakonstantinou1, C Verbeke, J Hastka, M Bohrer, R Hehlmann.   

Abstract

Previous reports have associated bcl-2 gene rearrangements found in non-Hodgkin's lymphomas with an inappropriately elevated bcl-2 expression compared with the mature B-cell stage of development. This study investigates bcl-2 expression in non-Hodgkin's lymphomas (NHL) without bcl-2 gene rearrangements. Molecular analysis in 168 patients with NHL revealed 45 patients without bcl-2 gene rearrangements in which additional immunostaining for bcl-2 protein was possible. An unexpectedly high prevalence (39/45) of bcl-2 expression was found. The levels and patterns of bcl-2 expression were not specific for the histological type of NHL and were similar to those shown in comparable cases with bcl-2 gene rearrangements. In conclusion, bcl-2 expression is not specific for NHL bearing bcl-2 gene rearrangements. This finding implicates the existence of other deregulating control mechanisms of bcl-2 expression, more important than bcl-2 gene rearrangements.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380403     DOI: 10.1046/j.1365-2141.2001.02727.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  Bone marrow immunohistology of plasma cell neoplasms.

Authors:  A Wei; S Juneja
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

2.  A case-control study of tobacco use and other non-occupational risk factors for lymphoma subtypes defined by t(14; 18) translocations and bcl-2 expression.

Authors:  Cindy M Chang; Jane C Schroeder; Andrew F Olshan; Cherie H Dunphy; Wen-Yi Huang; Ralph S Baric; Kathleen Conway; James R Cerhan; Charles F Lynch; Nathaniel Rothman; Kenneth P Cantor; Aaron Blair
Journal:  Cancer Causes Control       Date:  2010-03-16       Impact factor: 2.506

Review 3.  The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia.

Authors:  Gilad Itchaki; Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2016-07-08

4.  Non-Hodgkin lymphoma (NHL) subtypes defined by common translocations: utility of fluorescence in situ hybridization (FISH) in a case-control study.

Authors:  Cindy M Chang; Jane C Schroeder; Wen-Yi Huang; Cherie H Dunphy; Ralph S Baric; Andrew F Olshan; Kathleen C Dorsey; Georgette A Dent; James R Cerhan; Charles F Lynch; Nathaniel Rothman; Kenneth P Cantor; Aaron Blair
Journal:  Leuk Res       Date:  2009-06-07       Impact factor: 3.156

Review 5.  Frontline Therapy of CLL: Evolving Treatment Paradigm.

Authors:  Craig S Boddy; Shuo Ma
Journal:  Curr Hematol Malig Rep       Date:  2018-04       Impact factor: 3.952

6.  Analysis of follicular lymphoma by dual-color fluorescence in situ hybridization.

Authors:  Dakeun Lee; Jinwon Seo; YoungLyun Oh; Jinman Kim; YoungHyeh Ko
Journal:  Virchows Arch       Date:  2007-11-27       Impact factor: 4.064

7.  Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma.

Authors:  Hanan Mohamed Mahmoud; Yasmin Nabil El-Sakhawy
Journal:  Hematol Rep       Date:  2011-11-16

8.  The gene expression patterns of BMPR2, EP300, TGFβ2, and TNFAIP3 in B-Lymphoma cells.

Authors:  Dong-Mei He; Hong Wu; Xiu-Li Wu; Li Ding; Ling Xu; Yang-Qiu Li
Journal:  Cancer Biol Med       Date:  2014-09       Impact factor: 4.248

9.  Immunophenotyping of chronic B-cell neoplasms: flow cytometry versus immunohistochemistry.

Authors:  Afaf Abdel-Aziz Abdel-Ghafar; Manal Ahmed Shams El Din El Telbany; Hanan Mohamed Mahmoud; Yasmin Nabil El-Sakhawy
Journal:  Hematol Rep       Date:  2012-02-06

10.  Immunophenotypic features and t(14;18) (q32;q21) translocation of Chinese follicular lymphomas helps to distinguish subgroups.

Authors:  Fen Zhang; Li-Xu Yan; Su-Xia Lin; Zi-Yin Ye; Heng-Guo Zhuang; Jing-Ping Yun; Han-Liang Lin; Dong-Lan Luo; Fang-Ping Xu; Xin-Lan Luo; Jie Cheng; Ke-Ping Zhang; Yan-Hui Liu
Journal:  Diagn Pathol       Date:  2013-09-18       Impact factor: 2.644

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.